title: Antiviral effect of prolonged intermittent lymphoblastoid alpha interferon treatment in chronic hepatitis B.
abstract: In a European multicentre study 40 patients with HBeAg positive chronic hepatitis B virus (HBV) infection were treated with 5 mega units of lymphoblastoid alpha-interferon daily according to the following regimen: a four week primer course, four weeks of rest and a second course lasting 16 to 30 weeks. After 52 weeks of follow up, a response (HBeAg seroconversion and HBV-DNA negativity) was observed in 22 patients (55%). HBsAg seroconversion occurred in five patients (12.5%). One patient exhibited a relapse for serum HBeAg and HBV-DNA after cessation of treatment. According to a response prediction model, the observed response rate was not related to the selection of patients likely to respond. The initial interferon course induced a reduction of the serum HBV-DNA and HBeAg levels of 87% and 18%, respectively, leading to a significantly lower level of viral replication activity at the start of the second longterm course compared with baseline. After 24 weeks of follow up (week 16 of the second course), 19 (48%) patients exhibited a response, 13 (32%) a partial response (HBeAg < 50% of initial level or HBV-DNA negative) and 8 (20%) no response. For eight of the 13 partial responders treatment was stopped at week 24 and viral replication rebounded to pretreatment values. In the last five partial responders prolongation of therapy up to week 38 led to a definite response and HBsAg seroconversion in three of the five patients. The results of this study suggest that a short primer course and prolongation of therapy may help to enhance the response rate of alpha-interferon therapy for chronic hepatitis type B.
authors.affiliation: Department of Internal Medicine II, University Hospital Dijkzigt, Rotterdam, The Netherlands.
authors.forename: H L
authors.initials: HL
authors.lastname: Janssen
authors.forename: L
authors.initials: L
authors.lastname: Berk
authors.forename: S W
authors.initials: SW
authors.lastname: Schalm
authors.forename: R A
authors.initials: RA
authors.lastname: Heijtink
authors.forename: G
authors.initials: G
authors.lastname: Hess
authors.forename: S
authors.initials: S
authors.lastname: Rossol
authors.forename: K H
authors.initials: KH
authors.lastname: Meyer zum Buschenfelde
authors.forename: R A
authors.initials: RA
authors.lastname: Chamuleau
authors.forename: P L
authors.initials: PL
authors.lastname: Jansen
authors.forename: H W
authors.initials: HW
authors.lastname: Reesink
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001219:Aspartate Aminotransferases / Q000097:blood; D002908:Chronic Disease; D004279:DNA, Viral / Q000032:analysis; D004334:Drug Administration Schedule; D005260:Female; D006509:Hepatitis B / Q000276:immunology / Q000628:therapy*; D006513:Hepatitis B e Antigens / Q000032:analysis; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013997:Time Factors
chemical_list: D004279:DNA, Viral; D006513:Hepatitis B e Antigens; D016898:Interferon-alpha; D001219:Aspartate Aminotransferases